S.2730 changes how Medicare pays for new drugs, biologics, devices, and supplies used in dialysis care. It requires CMS to extend transitional add‑on payments (TDAPA/TPNIES) for renal innovations to at least three years, makes certain transitional add‑ons permanent under a statutory formula, and forces Medicare Advantage plans to make direct payments to providers that match those add‑ons.
The bill also revises what counts as a renal dialysis service, expands device eligibility (including breakthrough‑designated devices and capital assets), and adds a forecast‑error labor adjustment to the ESRD market‑basket update. For compliance officers, manufacturers, dialysis providers, and Medicare Advantage payors, S.2730 reshapes reimbursement certainty and reporting obligations while removing the requirement that these changes be budget neutral.
At a Glance
What It Does
The bill mandates a minimum three‑year transitional add‑on payment period for qualifying new renal dialysis drugs, biologics, and devices furnished on or after January 1, 2026, and establishes a statutory, permanent post‑TDAPA add‑on for drugs (set at 65% of a per‑service expenditure metric). It expands transitional device eligibility (including FDA breakthrough designation and capital assets) and requires Medicare Advantage plans to make direct provider payments equal to ESRD add‑ons during transitional periods. It also requires a forecast‑error adjustment to the ESRD market‑basket labor update beginning in 2026.
Who It Affects
Dialysis providers and renal dialysis facilities, manufacturers of renal drugs/biologics and dialysis devices, CMS (CMS contractors and payment systems), Medicare Advantage plans covering enrollees with ESRD, and Medicare beneficiaries receiving dialysis. Compliance and billing teams must adopt new modifiers and reporting practices.
Why It Matters
S.2730 shifts financial risk toward Medicare and away from providers/manufacturers during technology adoption windows, increases payment predictability for innovators, and forces MA plans to pay outside of capitation for transitional items — a substantive change to how innovations reach dialysis patients and how MA contracts and provider payments are administered.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
S.2730 targets three related payment problems that lawmakers say limit patient access to newer kidney treatments: short transitional payment windows that make adoption risky, device exclusions that leave capital‑intensive innovations unpaid, and labor‑indexing errors that undercompensate facilities. The bill lengthens transitional payment periods to at least three years for qualifying renal drugs and devices furnished from January 1, 2026, giving providers and manufacturers a longer predictable reimbursement window while a permanent payment is developed.
For drugs that receive TDAPA, the bill requires CMS to calculate a post‑TDAPA permanent add‑on tied to actual utilization and price data rather than forcing budget neutrality. The statute specifies the data hierarchy CMS must use (recent 12‑month utilization and the most recent ASP quarter; fallback to 100% of WAC if ASP is zero/negative; manufacturer invoice if WAC is unavailable), converts total expenditures into a per‑service figure, and sets the add‑on at 65% of that per‑service amount, with annual inflation updates.
CMS may not offset this by making other parts of the ESRD payment system budget neutral or by applying patient‑level case‑mix adjustments to the add‑on.On devices and supplies, S.2730 removes the longstanding exclusion that kept capital‑related assets out of the transitional add‑on and adds eligibility for devices that received expedited/breakthrough FDA review. For Medicare Advantage, the bill compels CMS to make direct payments to providers or renal dialysis facilities for the same transitional items and amounts that traditional Medicare would pay, for the duration of the transitional payment.
Finally, the bill instructs CMS to compute a forecast‑error adjustment to the ESRD market‑basket increase factor beginning in 2026 (initially accounting for cumulative errors from 2021–2022 and thereafter using the most recent year), and to apply that adjustment when the forecast error exceeds 0.5 percentage points.
The Five Things You Need to Know
The bill requires CMS to pay TDAPA/TPNIES for at least 3 years for qualifying renal drugs, biologics, and devices furnished on or after January 1, 2026.
For drugs leaving TDAPA, CMS must compute a permanent add‑on equal to 65% of per‑service spending (expenditures divided by number of dialysis services where the drug was administered), using recent 12‑month utilization and the latest ASP quarter as the primary data inputs.
If ASP data are zero or negative, the post‑TDAPA calculation must use 100% of wholesale acquisition cost (WAC); if WAC is unavailable, the manufacturer’s invoice is the fallback.
Beginning January 1, 2026, CMS must make Medicare Advantage direct payments to providers/facilities for the same transitional add‑ons and amounts determined under the ESRD prospective payment system, for the duration of the transitional payment period.
The bill adds a forecast‑error labor adjustment to the ESRD market‑basket update: initial adjustment in 2026 covers cumulative forecast error for 2021–2022; future adjustments use the most recent year and trigger when forecast error exceeds 0.5 percentage points.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Extend TDAPA to at least three years for renal drugs/biologics
This subsection amends regulatory pay provisions to require a minimum three‑year TDAPA period for qualifying renal dialysis drugs and biologics approved on or after January 1, 2020 and furnished on or after January 1, 2026. Practically, manufacturers and dialysis providers gain an extended transitional window to recover costs while utilization and price data accumulate; CMS must ensure systems accept claims under the extended timeframe.
Statutory post‑TDAPA add‑on for drugs (65% formula)
This is the operative change that makes a portion of TDAPA payments permanent. It prescribes the data inputs and fallbacks for the calculation (recent 12‑month utilization plus the latest ASP quarter; if ASP is zero/negative use 100% WAC; if WAC missing use manufacturer invoice), defines per‑service spending, fixes the add‑on at 65% of that per‑service amount, requires annual inflation updates, prevents budget‑neutral offsets, and disallows patient‑level case‑mix reductions. For implementers, this creates a deterministic, statutory calculation CMS must follow rather than an administrative rulemaking exercise.
Narrowing definition of renal dialysis services and AY modifier requirement
This amendment clarifies that drugs used primarily to treat comorbid conditions (e.g., cardiovascular disease, diabetes, cancer, obesity) approved after Dec 31, 2025 are excluded from the ESRD service definition unless they substitute for drugs already in the ESRD base rate. It also requires an AY (or successor) modifier on claims for such drugs furnished by dialysis providers, enabling CMS to flag and audit claims and separate ESRD‑specific therapy from broader comorbidity treatments.
TPNIES changes: 3‑year transitional period, breakthrough devices, and capital assets
Subsection (d) extends the transitional add‑on for new and innovative equipment and supplies to at least three years, explicitly makes devices with FDA expedited/breakthrough designation eligible as of Jan 1, 2026, and removes the regulatory exclusion that kept capital‑related assets out of transitional add‑ons. The result is that capital equipment (which previously might have been reimbursed only indirectly) can receive transitional add‑on payments, altering investment calculus for facilities and vendors.
Medicare Advantage direct payments for transitional ESRD items
This section inserts a new paragraph into the MA payment rules requiring CMS to make direct payment adjustments to providers or dialysis facilities for TDAPA/TPNIES items and amounts that mirror those under the ESRD PPS; the payments last for the transitional period. For MA plans, this overrides the usual capitated financial flow for these items and creates an operational path for providers to receive fee‑for‑service style add‑ons while enrollees remain in MA.
Forecast‑error labor adjustment to ESRD market basket
Title II amends the statutory ESRD update formula to require CMS to compute and apply a forecast‑error adjustment to the annual increase factor when the difference between forecasted and actual price change exceeds 0.5 percentage points. The initial 2026 computation must account for cumulative forecast error from 2021–2022; subsequent years use the most recent final year. The intent is to reduce under/over‑compensation arising from labor and input price forecasting errors.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Dialysis providers and renal facilities — receive longer transitional reimbursement windows, the prospect of a statutory permanent add‑on for certain drugs, and direct MA payments that reduce exposure to MA capitation volatility.
- Manufacturers of renal drugs, biologics, and devices — gain longer TDAPA/TPNIES coverage, clearer post‑TDAPA pricing rules with explicit fallbacks (WAC or invoice), and expanded device eligibility (breakthrough or capital assets), improving revenue predictability for product launches.
- Medicare Advantage enrollees with ESRD and dialysis patients — likely to see faster adoption of FDA‑approved renal innovations because providers face fewer immediate reimbursement gaps when offering new therapies or devices.
- Investors and innovators in renal technology — reduced reimbursement uncertainty and broader eligibility for capital‑intensive devices make commercial investment more attractive, potentially accelerating product development.
Who Bears the Cost
- Medicare program and federal payors — the statute explicitly disallows budget‑neutral offsets for the post‑TDAPA add‑on, increasing the likelihood of added Medicare spending and pressure on the trust fund unless Congress appropriates offsets elsewhere.
- Medicare Advantage plans — required direct payments for transitional items shift costs away from pure capitation; plans may face higher medical expense liability or seek contract changes with providers, potentially affecting premiums or supplemental benefits.
- CMS and contractors — implementation requires new claims logic (AY modifier enforcement), data aggregation for add‑on calculations, annual inflation updates, and coordination across FFS and MA payment streams, increasing administrative workload and IT changes.
- Dialysis facility billing and compliance teams — must adopt the new AY modifier, track utilization windows, and reconcile direct MA payments; facilities could face audits or payment recoupments if documentation does not support transitional claims.
Key Issues
The Core Tension
The bill pits two legitimate goals against each other: expanding and accelerating patient access to potentially transformative, often costly renal therapies versus preserving Medicare’s cost controls and predictable, equitable payment rules. Legislating generous, non‑budget‑neutral add‑ons and MA direct payments reduces adoption risk for providers and innovators but transfers financial risk to Medicare and taxpayers while creating new administrative complexity and potential perverse incentives.
The bill tilts reimbursement policy toward rapid adoption by guaranteeing transitional revenue streams and a legislated path to permanence for part of that revenue. That creates an inherent fiscal trade‑off: lowering adoption barriers for effective therapies but increasing Medicare spending and complicating the agency’s ability to control costs through budget neutrality.
The choice to fix the post‑TDAPA add‑on at 65% of a utilization‑based per‑service metric is administratively tidy, but it embeds assumptions about appropriate cost sharing between Medicare and providers that may not match real‑world variation in utilization, site‑of‑care, or dosing.
Operationally, the measurement rules invite gaming and data challenges. Using recent utilization and ASP as primary data sources is sensible when data are robust, but the statutory fallbacks (100% WAC or manufacturer invoice) may inflate price inputs for drugs with limited competition or negotiated discounts.
Requiring an AY modifier helps identify claims but imposes new documentation burdens and creates audit risk. For devices and capital assets, reimbursing capital through transitional add‑ons avoids complex depreciation schedules, but it also risks uneven payments across facilities with different investment and utilization patterns.
Finally, compelling MA direct payments addresses access gaps but clashes with MA’s capitated model; it may prompt contract re‑negotiations, upward pressure on premiums, or shifting of other covered services to compensate.
The forecast‑error labor adjustment stabilizes payments when CMS mispredicts input price changes, yet specifying a 0.5 percentage‑point trigger and requiring retroactive correction based on prior years introduces volatility into budget forecasting and provider budgeting. Implementation choices — e.g., the exact construction of the “appropriate mix of goods and services,” data lags, and the frequency of updates — will determine whether the adjustment smooths or amplifies payment swings.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.